This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01020487
First received: November 13, 2009
Last updated: February 13, 2017
Last verified: February 2017
November 13, 2009
February 13, 2017
February 2010
May 2014   (Final data collection date for primary outcome measure)
  • Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Blood samples were collected at hour 0, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours after dosing. ]
  • Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞) [ Time Frame: Blood samples were collected at hour 0, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours after dosing. ]
  • Part 2: Percentage of Participants Achieving Two Consecutive Reductions at Least 30% From Baseline in iPTH [ Time Frame: 12-week double-blind treatment period ]
    The primary efficacy endpoint was the percentage of participants who achieved two consecutive ≥ 30% reductions from baseline in intact parathyroid hormone (iPTH) levels during the 12 week double-blind portion of the study regardless of CKD stage.
The proportion of subjects who achieve at least two consecutive iIntact Parathyroid hormone (iPTH) values within the applicable Kidney Dialysis Outcomes Quality Initiatives (K/DOQI) iPTH target ranges [ Time Frame: 12 Weeks ]
Complete list of historical versions of study NCT01020487 on ClinicalTrials.gov Archive Site
  • Part 2: Percentage of Participants Achieving a Final iPTH Within KDOQI Target Ranges [ Time Frame: Week 12 ]

    The Kidney Disease Outcomes Quality Initiatives (KDOQI) Pediatric Subcommittee on Practice Guidelines for Bone Metabolism and Disease in Children with CKD target range for intact parathyroid hormone (iPTH) is as follows::

    CKD Stage 3: 35 - 69 pg/mL; CKD Stage 4: 70 - 110 pg/mL.

  • Part 2: Change From Baseline in iPTH to Each Post-baseline Visit [ Time Frame: Baseline and Weeks 2, 4, 8 and 12 ]
  • Part 2: Percentage of Participants Achieving Final Calcium Levels Within KDOQI Target Ranges [ Time Frame: Week 12 ]

    KDOQI recommends serum calcium is maintained within age appropriate normal ranges:

    Age 6 - 12: 9.4 - 10.2 mg/dL (2.35 - 2.55 mmol/L); Age 13 - 20: 8.8 - 10.2 mg/dL (2.20 - 2.55 mmol/L).

  • Part 2: Percentage of Participants Achieving Final Phosphorus Levels Within KDOQI Target Ranges [ Time Frame: Week 12 ]

    The KDOQI target ranges of serum phosphorus are to maintain at or above age appropriate lower limits and no higher than the age-appropriate upper limits:

    Age 6 - 12: 3.6 - 5.8 mg/dL (1.16 - 1.87 mmol/L); Age 13 - 20: 2.3 - 4.5 mg/dL (0.74 - 1.45 mmol/L).

  • Part 2: Change From Baseline in First Morning Void (FMV) Urinary Albumin to Creatinine Ratio (UACR) [ Time Frame: Baseline and Weeks 4, 8 and 12 ]
    The mean change from Baseline in FMV UACR on a log scale to each post baseline visit.
  • The proportion of subjects who achieve 2 consecutive >= 30% reductions in iPTH compared to baseline [ Time Frame: 12 Weeks ]
  • The mean percent change in iPTH over each visit [ Time Frame: 12 Weeks ]
  • The proportion of subjects who achieve 2 consecutive values within the K/DOQI target ranges for calcium and for phosphorus [ Time Frame: 12 Weeks ]
Not Provided
Not Provided
 
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease

Part 1: To determine the safety, tolerability, and pharmacokinetics of a single dose of 3 μg paricalcitol capsules in children ages 10 to 16 years with moderate to severe chronic kidney disease (CKD Stages 3 and 4).

Part 2: To determine the safety and efficacy of paricalcitol capsules as compared to placebo in decreasing serum intact parathyroid hormone (iPTH) in children ages 10 to 16 years with moderate to severe chronic kidney disease with an initial 12 weeks of double-blinded study drug followed by a minimum of 12 weeks of open-label active drug.

The study consists of two parts. Part 1 is an open-label single-dose, non-fasting, multicenter study to evaluate the pharmacokinetics (PK) of paricalcitol capsules in 12 children ages 10 to 16 years with CKD Stages 3 and 4. Part 2 of this study will be conducted as a 12 week randomized double-blind, placebo-controlled study, followed by 12 weeks open-label treatment. Participants active or enrolled under amendment 5 will enter a follow-up period and have study visits every 4 weeks until the final participant reaches Week 24.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Chronic Kidney Disease Stage 3 and 4
  • Drug: Paricalcitol
    Paricalcitol capsules taken with water.
    Other Name: Zemplar
  • Drug: Placebo
    Placebo capsules taken with water
  • Experimental: Part 1: Paricalcitol
    Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
    Intervention: Drug: Paricalcitol
  • Placebo Comparator: Part 2: Placebo
    Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
    Interventions:
    • Drug: Paricalcitol
    • Drug: Placebo
  • Experimental: Part 2: Paricalcitol
    Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
    Intervention: Drug: Paricalcitol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
December 2014
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject has chronic kidney disease Stage 3 or 4 as determined by estimated glomerular filtration rate (15 to 59 mL/min/1.73 m²) at Screening.
  • Subject is not expected to begin dialysis for at least 6 months (in the opinion of the investigator).
  • For entry into the Washout Period (for subjects who are currently on a vitamin D receptor activator [VDRA] and need to complete a 2 to 4 week washout), the subject must satisfy the following criteria based on the Screening laboratory values:

    • estimated glomerular filtration rate between 15 to 59 mL/min/1.73 m².
    • iPTH measurement that is greater than or equal to 60 pg/mL (Stage 3 subjects) or greater than or equal to 90 pg/mL (Stage 4 subjects).
    • An adjusted serum calcium value greater than or equal to 8.2 mg/dL (2.05 mmol/L) to less than or equal to 10.5 mg/dL (2.63 mmol/L).
    • A serum phosphorus value greater than or equal to 2.0 mg/dL (0.65 mmol/L but less than or equal to 6.0 mg/dL (1.94 mmol/L).
  • For entry into the Treatment Phase (vitamin D receptor activator naïve subjects and those that have completed a 4 week washout), the subject must have:

    • iPTH measurement that is greater than or equal to 75 pg/mL (Stage 3 subjects) or greater than or equal to 110 pg/mL (Stage 4 subjects).
    • An adjusted serum calcium value greater than or equal to 8.4 mg/dL (2.10 mmol/L) but less than or equal to 10.2 mg/dL (2.55 mmol/L).
    • A serum phosphorus value greater than or equal to 2.5 mg/dL (0.81 mmol/L) but less than or equal to 5.8 mg/dL (1.87 mmol/L).
    • Must have 25-hydroxyvitamin D levels ≥ 30 ng/mL prior to washout, if not VDRA naïve, or treatment in Part II of the study.

Exclusion Criteria:

  • All subjects that have had a small bowel transplant will be excluded from the study.
  • Subject has had acute kidney failure within 12 weeks of the Screening Phase (defined as an acute rise in serum creatinine).
  • Subject has had symptomatic or significant hypocalcemia requiring active vitamin D therapy (for example, calcitriol, paricalcitol, doxercalciferol or alfacalcidol) within 6 months prior to the Screening Phase.
  • Subject has a history of active kidney stones (6 months prior to screening).
  • Subject has chronic gastrointestinal disease, which in the investigator's opinion may cause significant gastrointestinal malabsorption.
  • Subject is taking maintenance calcitonin, bisphosphonates, cinacalcet, glucocorticoids in an equivalent dose of greater than 5 mg prednisone daily, or other drugs known to affect calcium or bone metabolism within 4 weeks prior to treatment.
Sexes Eligible for Study: All
10 Years to 16 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Germany,   Portugal,   Puerto Rico,   Singapore,   Spain,   United Kingdom,   United States
 
NCT01020487
M10-149
2010-019439-37 ( EudraCT Number )
No
Not Provided
Not Provided
Not Provided
AbbVie ( AbbVie (prior sponsor, Abbott) )
AbbVie (prior sponsor, Abbott)
Not Provided
Study Director: Deepa Chand, MD AbbVie
AbbVie
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP